Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/30840
Başlık: Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer
Yazarlar: Eskiler, Gamze Güney
Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.
0000-0002-1619-6680
0000-0002-2088-9914
0000-0002-3820-424X
Çeçener, Gülşah
Egeli, Ünal
Tunca, Berrin
6508156530
55665145000
6602965754
Anahtar kelimeler: Cell biology
Physiology
Multidrug resistance (MDR)
Nanoparticles
Solid lipid nanoparticles (SLNs)
Talazoparib
Triple negative breast cancer (TNBC)
Solid lipid nanoparticles
Parp inhibitor talazoparib
Multiple-drug resistance
P-glycoprotein
DNA-repair
BMN 673
Olaparib
Chemoresistance
Combination
Involvement
Yayın Tarihi: 3-Şub-2020
Yayıncı: Wiley
Atıf: Eskiler, G. G. vd. (2020). "Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer". Journal of Cellular Physiology, 235(9), 6230-6245.
Özet: Herein, we investigated efflux pumps-mediated talazoparib-resistance in the treatment of triple-negative breast cancer (TNBC). Furthermore, we produced a novel talazoparib-solid lipid nanoparticles (SLNs) and then explored in vitro therapeutic efficacy of talazoparib-SLNs to overcome talazoparib-resistance in TNBC cells. Talazoparib-SLNs formulation was produced and then characterized. Calcein and Rho-123 were used to analyze the functional activity of drug efflux pumps in these cells. Additionally, RT-PCR, western blot and immunofluorescence analysis were used to detect the messenger RNA, and protein expression level, and cellular localization of the multidrug resistance (MDR1), breast cancer resistance protein (BCRP), and MRP1. We found that talazoparib efflux was mediated by BCRP and MRP1 pumps in TNBC cells. Talazoparib-SLNs could significantly enhance therapeutic efficacy of talazoparib. Furthermore, talazoparib-SLNs were more effective in the suppression of MDR1, BCRP, and MRP1 gene and protein expression levels than talazoparib. Consequently, this study suggests that talazoparib-SLNs formulation represents a promising therapeutic carrier to reverse MDR-mediated resistance in TNBC.
URI: https://doi.org/10.1002/jcp.29552
https://onlinelibrary.wiley.com/doi/10.1002/jcp.29552
http://hdl.handle.net/11452/30840
ISSN: 0021-9541
1097-4652
Koleksiyonlarda Görünür:PubMed
Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.